Giá của Ensysce Biosciences, Inc. là bao nhiêu (ENSC)

Giá của Ensysce Biosciences, Inc. (ENSC) là $0.5275

Mũ thị trường của Ensysce Biosciences, Inc. là gì (ENSC)

Giới hạn thị trường của Ensysce Biosciences, Inc. (ENSC) là $1.25M

Thu nhập Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Năm	Thu nhập	Thay đổi
2026 (TTM)	$-10.97M	37.39%
2024	$-7.99M	-24.84%
2023	$-10.63M	-56.10%
2022	$-24.21M	-16.94%
2021	$-29.15M	18,017.11%
2020	$-160.88K	-98.41%
2019	$-10.10M	-477.51%
2018	$2.68M	-9,810.43%
2017	$-27.56K	0.00%

Năm

Thu nhập

Thay đổi

2026 (TTM)

$-10.97M

37.39%

2024

$-7.99M

-24.84%

2023

$-10.63M

-56.10%

2022

$-24.21M

-16.94%

2021

$-29.15M

18,017.11%

2020

$-160.88K

-98.41%

2019

$-10.10M

-477.51%

2018

$2.68M

-9,810.43%

2017

$-27.56K

0.00%

Công ty	Thu nhập	Chênh lệch thu nhập	Quốc gia
Novo Nordisk A/S NVO.US	$20.46B	-186,530.54%	DK
Vertex Pharmaceuticals Incorporated VRTX.US	$4.64B	-42,414.51%	US
Regeneron Pharmaceuticals, Inc. REGN.US	$5.23B	-47,768.53%	US
UCB SA UCB.BR	$2.14B	-19,581.29%	BE
CSL Limited CSL.AX	$1.61B	-14,811.33%	AU

Công ty

Thu nhập

Chênh lệch thu nhập

Quốc gia